TORONTO, Canada, April 4, 2024 – BlueDot Inc., a global leader in infectious disease intelligence, has been awarded on the Financial Times list of The Americas’ Fastest Growing Companies 2024. This prestigious award is presented by the Financial Times and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on April 4th, 2024, and can be viewed on the FT.com website.
The Americas’ Fastest Growing Companies 2024 ranking identifies companies with the strongest revenue growth between the years 2019 and 2022. The creation of the ranking was based on a four-step process:
- Application Phase: More than 30,000 eligible companies were invited to register. Only companies that met various criteria could apply for the ranking.
- Research Phase: Statista examined the officially stated revenue data of over 1000 publicly listed companies in the Americas, and added high-profile companies that met the criteria of minimum revenues in 2019 and 2022, independence and organic growth to the list.
- Evaluation Phase: The compound annual growth rate was calculated based on the revenue figures submitted and verified by the companies.
- Ranking: The top 500 companies that met various criteria were ranked. The minimum growth rate to be included was 9.00%
Based on the results of the study, BlueDot is immensely grateful to be recognized on the Financial Times list of The Americas’ Fastest Growing Companies 2024.
Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.
“We are thrilled to receive this recognition which reflects our efforts to tackle the growing global threat of emerging and re-emerging infectious disease outbreaks”, expressed Dr. Kamran Khan, founder and CEO of BlueDot. “Our scientific and technological innovations, coupled with our expanding global business are empowering governments, pharma companies, and private enterprises, in service of protecting the lives and livelihoods of millions worldwide”.
